Myomo (MYO) Q2 2026 earnings summary

Executive summary

• Revenue for Q2 2026 rose 21% year-over-year to $11.7 million, driven by higher ASP and unit volume, with 53% of revenue from recurring patient sources, up from 26% a year ago.

• Operating leverage improved as revenue grew while operating expenses remained nearly flat.

• Record 255 MyoPro orders were received in the quarter, up 23% year-over-year.

• Strategic focus on recurring referrals, expanded reimbursement, operational efficiency, and innovation is yielding measurable progress.

• Full-year revenue guidance was raised to $45–$47 million, reflecting anticipated 10–15% growth over the prior year.

Financial highlights

• Gross margin improved to 72.1% from 62.7% in Q2 2025, aided by higher ASP and cost reductions.

• Operating loss narrowed to $2.3 million from $4.6 million a year ago; net loss was $4 million ($0.09/share), compared to $4.6 million ($0.11/share) in Q2 2025.

• Adjusted EBITDA loss improved to $800,000 from $4 million, a 79% improvement.

• Cash and short-term investments at June 30, 2026, totaled $13.5 million; cash used in operations was $1.9 million, down from $8.9 million a year ago.

• Operating expenses were $10.7 million, up less than 1% year-over-year.

Outlook and guidance

• Q3 2026 revenue expected between $11.5 million and $12 million, up 14%-19% year-over-year.

• Full-year 2026 revenue guidance raised to $45-$47 million from $43-$46 million.

• Operating expenses to grow modestly in Q3; full-year OpEx growth to be limited to half the rate of revenue growth.

• Total cash burn for H2 2026 expected to be less than $2 million.

• Sufficient liquidity is expected for at least the next 12 months.